RESULTS:
In patients without (n=130) and with VF (n=114), RNA and DNA showed resistance 37 to at least one drug of the rilpivirine/emtricitabine/tenofovir combination in 8% and 9% and 38 in 60% and 45%, respectively. For rilpivirine RAM, correlation between RNA and DNA was 39 higher in patients without VF than in patients with VF (kappa= 0.60 versus 0.19, p=0.026). 40 Overall, prevalence of RAM was lower in DNA than in RNA. 41 CONCLUSION: The incomplete information provided by DNA genotypic test is more notable 42 in patients with VF, suggesting that all resistance mutations associated with prior VF have 43 not been archived in the proviral DNA or decreased to a level below threshold of detection. 44 In the case where no historical plasma genotypic test is available, DNA testing might be 45 useful to rule out switching to rilpivirine/emtricitabine/tenofovir. The second generation NNRTI rilpivirine (RPV) formulated in a single tablet regimen (STR) 53 with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) was approved by the 54 European Medicines Agency and the US Food and Drug Administration as a once-daily oral 55 treatment for adults infected with HIV-1 without mutations associated with resistance to 56 TDF, FTC, or the NNRTI class, and harboring a viral load (VL) ≤100 000 HIV-1 RNA copies/mL. 57 Current antiretroviral treatment guidelines recommend switching therapy in virologically 58 suppressed patients to improve adherence or tolerability or to allow for treatment 59 simplification 1-3 . The SPIRIT study showed maintenance of virologic suppression at W48 for 60 89.3% of patients switching to rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) from a 61 ritonavir-boosted protease inhibitor (PI/r)-based regimen, compared with those who 62 continued treatment with a PI/r regimen with a low risk of virologic failure (VF) 4 . A study 63 demonstrated switching from efavirenz (EFV/FTC/TDF to RPV/FTC/TDF) was safe and 64 effective for virologically suppressed HIV-infected patients with EFV intolerance 5 . Cohort 65 studies have also shown efficacy and tolerability of switching to RPV/FTC/TDF 6 . Thus 66 RPV/FTC/TDF is considered as an appropriate therapy for switch for simplification in 67 virologically suppressed HIV infected patient. 68 In this context, the use of previous plasma resistance genotypes was recommended to 69 determine the susceptibility to this combination 3 because of the possible presence of pre-70 existing drug resistance mutations leading to VF. Studies have shown that resistance testing 71 performed on HIV DNA lacks sensitivity compared with accumulated drug resistances from 72 previous plasma genotypes. 7, 8 However in patients fully virologically suppressed, the 73 previous plasma genotypic test could be unavailable. 74 In the perspective of a switch to the combination RPV/TDF/FTC, the aim of this study was to 75 determine whether proviral DNA is a potential relevant alternative to HIV-RNA for resistance 76 genotyping in HIV-1 infected treated patients with at least one year of virologic suppression. In 244 HIV-1 infected patients treated in 2 centers (Nantes University Hospital and Pitié-80 Salpêtrière Hospital) with a prior available RNA resistance test, we retrospectively analyzed 81 HIV DNA resistance genotype generated in PBMC after at least one year of virologic success 82 (VL <50 copies/mL). Bulk sequences of the reverse transcriptase (RT) on RNA and DNA were 83 determined using the ANRS consensus technique primer sequences described at 84 http://www.hivfrenchresistance.org. We compared prevalence of HIV resistance mutations in 85 the DNA and RNA genotype generated from the last detectable VL. We studied 2 groups of 86 patients: 130 patients without previous VF (pre-therapeutic plasma genotype) and 114 87 patients with at least one previous VF (genotype on the more recent detectable VL) 88 regardless of the treatment they received (VF was defined as two consecutive VL>50 89 copies/mL). In patients without VF, the prevalence of studied resistance associated mutation (RAM) was 109 very low in both RNA and DNA RT sequences (Figure 1a) , with resistance to at least one drug 110 of the RPV/FTC/FTC combination in 8.0% and 9.0%, respectively. 111 In patients with at least one prior VF, the prevalence of at least one RPV RAM was 24.6% and In patients without VF, concordance between resistance in RNA and DNA was not 119 significantly higher than in patients with VF (kappa= 0.57 versus 0.43 respectively, p=0.36). 120 For RPV RAM, correlation between RNA and DNA was significantly higher in patients without 121 VF than in patients with at least one VF (kappa= 0.60 versus 0.19 respectively, p=0.026). 122 Overall, prevalence of rilpivirine associated mutations was lower in DNA than in RNA 123 genotypic test, except for mutations at positions E138 and M230 that are APOBEC driven 124 mutations (G to A) ( Figure 1b ). The factors associated with a good correlation between 125 resistance according RNA and DNA genotype were a higher VL at RNA genotype (p=0.0124), In the context of switch to RPV/TDF/FTC therapy in HIV-1 infected treated patients, this 133 study shows a good concordance between DNA and RNA genotypes in patients without prior 134 VF and who are successfully suppressed for at least one year. However, DNA genotype is less 135 informative than RNA genotype in patients with at least one prior VF. The good concordance 136 in patients with no prior VF is in accordance with results of studies on naive patients showing 137 that DNA genotype could be useful and even more informative than standard RNA 138 genotyping 10,11 . 139 In patients with at least one prior VF, the rate of selected resistance associated mutations to 140 RPV in RNA was somewhat lower than in previous studies conducted in patients pre-exposed 141 to an NNRTI-based regimen but naive to RPV 12-14 . Indeed, in our study the 3 main RPV 142 RAMs at codons 181, 101 and 138 had a frequency of 12.3, 2.6 and 5.3% versus 18 to 22.6%, 143 7 to 20.5% and 5.3 to 14% in these 3 studies, respectively. This lower frequency could be due 144 to the fact that our studied population not exclusively contained NNRTI failing patients, 145 nevertheless the 3 mains RPV RAM are similar to those observed in others studies. In the HIV 146 DNA, we showed a lower prevalence of the RPV RAM: 101, 181 and 221 with 0.9%, 3.5% and 147 0.9% versus 7%, 18% and 4% in the study of Gallien et al 12 . However, patients of this study 148 were selected to have a prior VF especially to NVP or EFV and had a prior history of triple 149 class failure. 150 In patients with prior VF, our study generally confirmed results of previous studies on the 151 discordance between DNA and RNA genotypes. Indeed, in a large number of patients with 152 undetectable or low VL under treatment, a study showed a concordance between DNA and 153 RNA of 26.3% for NNRTI mutations 7 . Another study demonstrated that mutations conferring 154 resistance to at least one antiretroviral drug were detected exclusively by RNA genotyping or 155 exclusively by DNA genotyping in 47% and 1% of patients for NNRTIs, respectively 8 . 156 Overall, prevalence of RAM was generally lower in DNA than in RNA genotypic tests, except 157 for mutations at positions E138 and M230 that are APOBEC driven mutations. Indeed, 158 APOBEC induces G to A viral mutation and this mechanism could explain the persistence of 159 mutations in archived cellular proviral DNA 15 . 160 The incomplete information provided by the DNA test is more notable in patients with at 161 least one prior VF, suggesting that all resistance mutations associated with the prior VF may 162 not have been archived in the proviral DNA or not detected with classical Sanger sequencing. 163 A good correlation between prior RNA genotype and current DNA genotype was significantly 
Number of lines of treatment

